ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis

Go back to ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 16.59 +0.36 (2.22%)
Previous Close $16.23    52 Week High $42.49 
Open $16.23    52 Week Low $16.64 
Day High $16.64    P/E N/A 
Day Low $15.92    EPS $-0.42 
Volume 293,711